A new technical paper titled “Hybrid tungsten oxyselenide/graphene electrodes for near-lossless 2D semiconductor phase ...
All-optical image processing has been viewed as a promising technique for its high computation speed and low power ...
A U.S. specialty biopharmaceutical company focused on dermatology, with operations centered on commercialization and late-stage development. The company is publicly listed on NYSE American under ...
Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral ...
In January 2022, Garutadustat, the innovative, potentially best-in-class, oral PHD inhibitor was nominated as a preclinical ...
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing ...
Insilico Medicine (3696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of ...
Bicara Therapeutics (NASDAQ:BCAX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
The FDA clears ProlivRx at-home neuromodulation for adjunctive major depressive disorder treatment in adults with inadequate antidepressant response.
iOnctura CEO to present at the 2026 J.P. Morgan Healthcare Conference -- Participation underscores growing excitement around company's momentum and potential in precision oncology ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback